Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

  • Bailón, Lucía|||0000-0001-7277-9314
  • Moltó, José|||0000-0003-4564-1963
  • Curran, Adrian|||0000-0002-1263-0814
  • Cadiñanos, Julen
  • López Bernaldo de Quirós, Juan Carlos|||0000-0002-8989-9758
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Ambrosioni, Juan|||0000-0001-9931-6686
  • Imaz, Arkaitz|||0000-0001-8411-1952
  • Benet, Susana|||0000-0002-2219-8826
  • Suanzes, Paula|||0000-0002-6871-0098
  • Navarro, Jordi|||0000-0002-7187-0367
  • González García, Juan|||0000-0002-3652-002X
  • Busca, Carmen
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Berenguer, Juan|||0000-0001-8541-8200
  • García-Fraile Fraile, Lucio|||0000-0002-2512-6107
  • Mejía-Abril, Gina
  • Miró, José M.|||0000-0001-8057-7755
  • Scévola, Sofia|||0000-0003-3578-5031
  • Moreno, Santiago|||0000-0002-2843-1094
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Tian, Yuan
  • Frankot, Michelle
  • Lim, Daina
  • Cai, Yanhui
  • Vendrame, Elena
  • Guo, Susan
  • Wallin, Jeffrey J.
  • Geleziunas, Roman
  • Sengupta, Devi
  • Alarcón-Soto, Yovaninna|||0000-0002-9977-8634
  • Leal, Isabel
  • Aranguen, Alvaro
  • Garcia-Garcia, Margarida
  • McGowan, Ian
  • Brander, Christian|||0000-0002-0548-5778
  • Arribas, José Ramón
  • Mothe, Beatriz|||0000-0001-9975-407X
.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection, a randomized, placebo-controlled phase 1 trial

  • Bailón, Lucía|||0000-0001-7277-9314
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • Escribà, Tuixent|||0000-0001-9467-7802
  • Rosás-Umbert, Miriam|||0000-0002-2850-6586
  • Parera, Mariona|||0000-0002-0756-8307
  • Casadellà, Maria|||0000-0002-4115-2305
  • Lopez, Miriam
  • Pérez, Francisco
  • Oriol-Tordera, Bruna|||0000-0002-2714-9097
  • Ruiz Riol, Marta|||0000-0003-1899-8879
  • Coll, Josep
  • Pérez, Félix|||0000-0002-6799-9272
  • Rivero, Ángel|||0000-0003-2136-0702
  • Leselbaum, Anne R.
  • McGowan, Ian
  • Sengupta, Devi
  • Wee, Edmund G.
  • Hanke, Tomáš|||0000-0002-6076-9546
  • Paredes, Roger|||0000-0002-6553-691X
  • Alarcón-Soto, Yovaninna|||0000-0002-9977-8634
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Brander, Christian|||0000-0002-0548-5778
  • Moltó, José|||0000-0003-4564-1963
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Barriocanal, Ana María|||0000-0002-4159-519X
  • Benet, Susana|||0000-0002-2219-8826
  • Cobarsi, Patricia|||0000-0003-3977-230X
  • Geleziunas, Romas
  • Loste, Cora
  • Meulbroek, Michael
  • Miranda, Cristina
  • Muñoz-Moreno, José Antonio|||0000-0002-7239-5422
  • Naval, Jordi
  • Nieto Gil-Ortega, Aroa|||0000-0001-8477-5062
  • Pujol Vila, Ferran|||0000-0002-6811-2426
  • Puig, Jordi|||0000-0002-4075-0346
HIVACAT T-cell immunogen (HTI) is a novel human immunodeficiency virus (HIV) vaccine immunogen designed to elicit cellular immune responses to HIV targets associated with viral control in humans. The AELIX-002 trial was a randomized, placebo-controlled trial to evaluate as a primary objective the safety of a combination of DNA.HTI (D), MVA.HTI (M) and ChAdOx1.HTI (C) vaccines in 45 early-antiretroviral (ART)-treated individuals (44 men, 1 woman; NCT03204617). Secondary objectives included T-cell immunogenicity, the effect on viral rebound and the safety of an antiretroviral treatment interruption (ATI). Adverse events were mostly mild and transient. No related serious adverse events were observed. We show here that HTI vaccines were able to induce strong, polyfunctional and broad CD4 and CD8 T-cell responses. All participants experienced detectable viral rebound during ATI, and resumed ART when plasma HIV-1 viral load reached either.